Probiotics for Gallstones in Post-bariatric Surgery Patients

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Obesity is an increasing epidemic worldwide and has a significant impact on human health and socioeconomics. Multiple studies have shown that bariatric surgery increases the risk of postoperative gallbladder stones. Contributing factors to gallstone formation include gallbladder motility and bile supersaturation due to rapid weight loss and cholesterol mobilization. At present, the prevention and treatment of gallbladder stones in obese patients after bariatric surgery are still controversial. In recent years, the study of ursodeoxycholic acid in preventing gallbladder stone formation after bariatric surgery has become a research hotspot. At the same time, other studies have shown that taking probiotics or digestive enzymes may improve gastrointestinal symptoms and improve quality of life after bariatric surgery. Therefore, the purpose of this study was to determine the ability of probiotics to prevent gallstone formation after bariatric surgery and to evaluate the impact of oral probiotics on quality of life in patients after bariatric surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 60
Healthy Volunteers: f
View:

• Patients receiving bariatric surgery for morbid obesity

• Patiets at ages between 20 to 60 y/o

• Patients willing to follow up regulary after bariatric surgery

Locations
Other Locations
China
Shandong Linglong Yingcheng Hospital
RECRUITING
Yantai
Contact Information
Primary
Xuan Qiu, MD
qiuxuan100@163.com
8618354280081
Backup
Ni Wang, MD,PD
wangni1989@163.com
8618705353551
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2025-06-01
Participants
Target number of participants: 400
Treatments
Experimental: Ursodoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months
Experimental: Bifidobacterium group
Bifidobacteria, 210 mg po tid x 6 months
Experimental: Bifidobacterium and ursodeoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months Bifidobacteria, 210 mg po tid x 6 months
Related Therapeutic Areas
Sponsors
Leads: Shandong Linglong Yingcheng Hospital

This content was sourced from clinicaltrials.gov